Toujeo
Active Ingredient(s): Insulin GlargineFDA Approved: * February 25, 2015
Pharm Company: * SANOFI AVENTIS US
Category: Diabetes
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Toujeo Overview
Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes.[3] It is typically the recommended long acting insulin in the United Kingdom.[4] It is used once a day as an injection just under the skin.[3] Effects generally begin an hour after use.[3] Common side effects include low blood sugar, problems at the site of injection, itchiness, and weig...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Insulin_glargine
Recent Toujeo Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Insulin Glargine
- Injection: 100 Units/ml, 100unit/ml, 300 Units/ml
- Solution: 300 Units/3ml (100 Units/ml), 300 Units/ml (300 Units/ml), 300units/ml (300units/ml), 450 Units/1.5ml (300 Units/ml), 900 Units/3ml (300 Units/ml)
NDC Database Records for Toujeo: (2 results)
Sorted by National Drug Code- 0024-5869 Toujeo 300 U/Ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
- 50090-2193 Toujeo 300 U/Ml Subcutaneous Injection, Solution by A-s Medication Solutions
Other drugs which contain Insulin Glargine or a similar ingredient: (5 results)
- BASAGLAR Insulin Glargine1 discussion
- INSULIN GLARGINE
- SEMGLEE Insulin Glargine
- INSULIN GLARGINE + LIXISENATIDE
- SOLIQUA Insulin Glargine + Lixisenatide